Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
8.14
-0.27 (-3.21%)
Dec 26, 2025, 4:00 PM EST - Market closed
Personalis Employees
As of December 31, 2024, Personalis had 229 total employees, including 228 full-time and 1 part-time employees. The number of employees increased by 4 or 1.78% compared to the previous year.
Employees
229
Change (1Y)
4
Growth (1Y)
1.78%
Revenue / Employee
$301,760
Profits / Employee
-$322,633
Market Cap
722.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 229 | 4 | 1.78% |
| Dec 31, 2023 | 225 | -174 | -43.61% |
| Dec 31, 2022 | 399 | 73 | 22.39% |
| Dec 31, 2021 | 326 | 91 | 38.72% |
| Dec 31, 2020 | 235 | 53 | 29.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PSNL News
- 10 days ago - Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors - Business Wire
- 16 days ago - New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer - Business Wire
- 5 weeks ago - Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 6 weeks ago - Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer - Business Wire
- 7 weeks ago - Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Personalis Reports Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Personalis to Announce Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing - Business Wire